1. Home
  2. Stocks
  3. Natcopharm Share Price
  • Chart
  • Rating
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • Similar Stocks
  • FAQs

    • Natco Pharma Share Price

    Large Cap
    ₹1,421.95
    + 12.95 (0.92%)
    05 November, 2024 16:13 BSE: 524816 NSE: NATCOPHARM ISIN: INE987B01026

    Start SIP in Natco Pharma

    Start SIP

    Natco Pharma Performance

    Day Range

    • Low 1,403
    • High 1,428
    ₹ 1,421

    52 Week Range

    • Low 729
    • High 1,639
    ₹ 1,421
    • Open Price1,409
    • Previous Close1,409
    • Volume273870

    Natco Pharma Chart

    • Over 1 Month + 5.02%
    • Over 3 Month + 3.97%
    • Over 6 Month + 37.51%
    • Over 1 Year + 91.23%

    Natco Pharma Key Statistics

    P/E Ratio 15.6
    PEG Ratio 0.2
    Market Cap Cr 25,469
    Price to Book Ratio 4.3
    EPS 73.1
    Dividend 0.4
    Relative Strength Index 52.14
    Money Flow Index 44.32
    MACD Signal -24.54
    Average True Range 45.42

    Natco Pharma Investment Rating

    • Master Rating:

    • NATCO Pharma Ltd. is a leading Indian pharmaceutical company specializing in generic and specialty medicines, including oncology, cardiology, and central nervous system therapies. It serves global markets with a focus on affordable and high-quality healthcare solutions. Natco Pharma has an operating revenue of Rs. 4,220.90 Cr. on a trailing 12-month basis. An annual revenue growth of 47% is outstanding, Pre-tax margin of 42% is great, ROE of 23% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 50DMA and around 20% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 14% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 85 which is a GOOD score indicating consistency in earnings, a RS Rating of 77 which is FAIR indicating the recent price performance, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 35 indicates it belongs to a strong industry group of Medical-Diversified and a Master Score of A is the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail. Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

    EPS Strength

    Price Strength

    Buyer Demand

    Group Rank

    Natco Pharma Financials
    IndicatorJun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Oper Rev Qtr Cr 1,2379656259311,048781
    Operating Expenses Qtr Cr 474512387488545454
    Operating Profit Qtr Cr 763453238442504328
    Depreciation Qtr Cr 405240404038
    Interest Qtr Cr 454331
    Tax Qtr Cr 1228332647052
    Net Profit Qtr Cr 636349192360405254
    IndicatorMar 2024Mar 2023
    Total Revenue Annual Cr 3,6742,437
    Operating Expenses Annual Cr 1,9321,506
    Operating Profit Annual in Cr 1,637845
    Depreciation Cr 172151
    Interest Annual Cr 159
    Tax Annual Cr 249134
    Net Profit Annual Cr 1,307637
    IndicatorMar 2024Mar 2023
    Cash from Operating Activity Annual Cr 1,196784
    Cash from Investing Activity Annual Cr -961-437
    Cash from Financing Annual Activity Cr -237-347
    Net Cash Flow Annual Cr -11
    IndicatorMar 2024Mar 2023
    Total ShareHolders Funds Annual Cr 5,5924,702
    Fixed Assets Annual Cr 2,4212,297
    Total Non Current Assets Annual Cr 3,1442,893
    Total Current Assets Annual Cr 3,4102,495
    Total Assets Annual Cr 6,5545,388
    IndicatorMar 2024Mar 2023
    Book Value Per Share Annual Rs 312258
    ROE Annual % 2314
    ROCE Annual % 2816
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 4940
    IndicatorJun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Oper Rev Qtr Cr 1,3631,0687591,0311,141898
    Operating Expenses Qtr Cr 558571491573613559
    Operating Profit Qtr Cr 805497268458528339
    Depreciation Qtr Cr 445644444441
    Interest Qtr Cr 565443
    Tax Qtr Cr 1359144718049
    Net Profit Qtr Cr 669386213369420276
    IndicatorMar 2024Mar 2023
    Total Revenue Annual Cr 4,1272,812
    Operating Expenses Annual Cr 2,2471,772
    Operating Profit Annual in Cr 1,751936
    Depreciation Cr 187164
    Interest Annual Cr 1915
    Tax Annual Cr 285147
    Net Profit Annual Cr 1,388715
    IndicatorMar 2024Mar 2023
    Cash from Operating Activity Annual Cr 1,212849
    Cash from Investing Activity Annual Cr -1,033-477
    Cash from Financing Annual Activity Cr -247-363
    Net Cash Flow Annual Cr -689
    IndicatorMar 2024Mar 2023
    Total ShareHolders Funds Annual Cr 5,8534,874
    Fixed Assets Annual Cr 2,5722,436
    Total Non Current Assets Annual Cr 2,8832,657
    Total Current Assets Annual Cr 4,0243,000
    Total Assets Annual Cr 6,9065,657
    IndicatorMar 2024Mar 2023
    Book Value Per Share Annual Rs 327267
    ROE Annual % 2415
    ROCE Annual % 2918
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 4738
    Invest in Natco Pharma

    Natco Pharma Technicals

    EMA & SMA

    Current Price
    ₹1,421.95
    + 12.95 (0.92%)
    pointer
    • Bullish Moving Average
    • ___
    • 15
    • Bearish Moving Average
    • ___
    • 1
    • 20 Day
    • ₹1,387.21
    • 50 Day
    • ₹1,402.09
    • 100 Day
    • ₹1,345.92
    • 200 Day
    • ₹1,212.24
    • 20 Day
    • ₹1,385.54
    • 50 Day
    • ₹1,453.97
    • 100 Day
    • ₹1,374.49
    • 200 Day
    • ₹1,171.74

    Natco Pharma Resistance and Support

    PIVOT
    ₹1,412.34
    Resistance
    First Resistance 1,428.62
    Second Resistance 1,448.23
    Third Resistance 1,464.52
    RSI 52.14
    MFI 44.32
    MACD Single Line -24.54
    MACD -14.10
    Support
    First Support 1,392.72
    Second Support 1,376.43
    Third Supoort 1,356.82

    Natco Pharma Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day 326,485 16,206,715 49.64
    Week 325,986 15,777,742 48.4
    1 Month 662,361 29,481,703 44.51
    6 Month 1,010,828 45,355,856 44.87

    Natco Pharma Result Highlights

    Natco Pharma Synopsis

    NSE-Medical-Diversified

    NATCO Pharma Ltd. is a prominent pharmaceutical company in India, recognized for its expertise in producing high-quality generic and specialty medicines. The company has a strong focus on therapeutic areas such as oncology, cardiology, gastroenterology, and the central nervous system. NATCO is committed to providing affordable healthcare solutions, making essential medications accessible to patients worldwide. It has a significant presence in both the domestic and international markets, including the U.S., Europe, and Asia. Known for its innovation in drug development and manufacturing, NATCO continues to expand its product portfolio while adhering to stringent global regulatory standards, ensuring safe and effective treatments.
    Market Cap 25,237
    Sales 3,758
    Shares in Float 8.96
    No of funds 377
    Yield 0.39
    Book Value 4.51
    U/D Vol ratio 1
    LTDebt / Equity
    Alpha 0.19
    Beta 0.72

    Natco Pharma Shareholding Pattern

    Owner NameSep-24Jun-24Mar-24Dec-23
    Promoters 49.62%49.71%49.71%49.71%
    Mutual Funds 2.37%2.67%4.08%5.2%
    Insurance Companies 4.23%5.09%5.58%6.04%
    Foreign Portfolio Investors 17.51%17.45%16.14%13.72%
    Financial Institutions/ Banks
    Individual Investors 22.6%21.59%20.61%21.24%
    Others 3.67%3.49%3.88%4.09%

    Natco Pharma Management

    Name Designation
    Mr. V C Nannapaneni Chairman & Ind.Director
    Mr. Rajeev Nannapaneni Director & CEO
    Mr. P S R K Prasad Director & Exe. VP (Corp. Engg. Services)
    Dr. D Linga Rao Director & President (Tech. Affairs)
    Dr. Pavan Ganapati Bhat Director
    Mr. D Vijaya Bhaskar Independent Director
    Mr. A D M Chavali Independent Director
    Dr. Kantipudi Suma Addnl. & Ind.Director
    Mr. Nitin Jain Addnl. & Ind.Director
    Mr. Lakshminarayana Bolisetty Addnl. & Ind.Director

    Natco Pharma Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    Natco Pharma Corporate Action

    Date Purpose Remarks
    2024-11-12 Quarterly Results & Interim Dividend
    2024-08-12 Quarterly Results & Interim Dividend
    2024-05-27 Audited Results
    2024-02-14 Quarterly Results & Interim Dividend
    2023-11-14 Quarterly Results & Interim Dividend
    Date Purpose Remarks
    2024-08-23 INTERIM Rs.3.00 per share(150%)Interim Dividend
    2024-02-26 INTERIM Rs.1.25 per share(62.5%)Third Interim Dividend
    2023-11-24 INTERIM Rs.1.25 per share(62.5%)Second Interim Dividend
    2023-08-22 INTERIM Rs.7.00 per share(350%)Interim Dividend
    2023-02-21 INTERIM Rs.1.25 per share (62.5%) Third Interim Dividend

    About Natco Pharma

    Natco Pharma Ltd. is leading pharmaceutical company in India, specializing in production of generic medicines, bulk drugs, & specialty pharmaceuticals. Founded in 1981, Natco has established itself as key player in global pharmaceutical industry, with strong focus on oncology, cardiology, & gastroenterology segments. company operates state of the art manufacturing facilities that comply with global regulatory standards, ensuring production of high quality medicines. Natco Pharma is known for its innovation, particularly in development of affordable generic versions of high cost drugs, which has made it preferred partner for healthcare providers worldwide.

    NATCO Pharma Limited (NATCO) is pharmaceutical firm that focuses on research & development & is vertically integrated. Its core competencies include creating, producing, & selling complicated pharmaceuticals for specific therapeutic areas. NATCO is now present in three business categories of contract manufacturing business, active pharmaceutical ingredients (APIs), & final dosage formulations (FDF).
     

    Natco Pharma FAQs

    What is Share Price of Natco Pharma ?

    Natco Pharma share price is ₹1,421 As on 05 November, 2024 | 15:59

    What is the Market Cap of Natco Pharma ?

    The Market Cap of Natco Pharma is ₹25468.5 Cr As on 05 November, 2024 | 15:59

    What is the P/E ratio of Natco Pharma ?

    The P/E ratio of Natco Pharma is 15.6 As on 05 November, 2024 | 15:59

    What is the PB ratio of Natco Pharma ?

    The PB ratio of Natco Pharma is 4.3 As on 05 November, 2024 | 15:59

    Is it good time to buy Natco Pharma shares?

    Evaluate company's performance in pharmaceutical industry & its product pipeline before investing
     

    What are most important metrics that can help to analyze share price of Natco Pharma?

    Key metrics include revenue growth, product approvals, & profit margins.

    How can you buy shares from Natco Pharma?

    Open Demat account with 5 Paisa Capital & post doing KYC & active account search for Natco Pharma share, you can then put order as you prefer.

    Open Free Demat Account

    Be a part of 5paisa community - The first listed discount broker of India.

    +91
     
    footer_form

    Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

    Q2FY23

    5paisa Capital Ltd. CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI-registered Mutual Fund Distributor | AMFI REGN No.: ARN-104096 | Date of initial Registration: 30/07/2015 | Current validity of ARN : 30/07/2027 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of ₹10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Mutual Fund, Mutual Fund-SIP are not Exchange traded products, and the Member is just acting as distributor. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support Desk Helpline: 8976689766

    Contact Us

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

    Email: support@5paisa.com

    Support Desk Helpline: 8976689766

    ©2024, 5paisa Capital Ltd. All Rights Reserved. We are ISO 27001:2013 Certified.